This company listing is no longer active
BLPH Stock Overview
A clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Bellerophon Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.012 |
| 52 Week High | US$0.10 |
| 52 Week Low | US$0.01 |
| Beta | 0.75 |
| 1 Month Change | -68.42% |
| 3 Month Change | -65.71% |
| 1 Year Change | -65.71% |
| 3 Year Change | -99.59% |
| 5 Year Change | -99.77% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Bellerophon Therapeutics (NASDAQ:BLPH) Will Have To Spend Its Cash Wisely
Jan 06
Bellerophon stock gains ~24% after getting FDA nod to reduce phase 3 study size
Sep 27Bellerophon Therapeutics GAAP EPS of -$0.43 beats by $0.17
Aug 15Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?
Jan 18Bellerophon Therapeutics EPS misses by $0.01
Nov 05Shareholder Returns
| BLPH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -36.8% | 2.3% | -0.4% |
| 1Y | -65.7% | -1.4% | 20.8% |
Return vs Industry: BLPH underperformed the US Biotechs industry which returned 1.3% over the past year.
Return vs Market: BLPH underperformed the US Market which returned 24% over the past year.
Price Volatility
| BLPH volatility | |
|---|---|
| BLPH Average Weekly Movement | 38.1% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BLPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BLPH's weekly volatility has increased from 23% to 38% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 18 | Craig Jalbert | bellerophon.com |
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness.
Bellerophon Therapeutics, Inc. Fundamentals Summary
| BLPH fundamental statistics | |
|---|---|
| Market cap | US$146.79k |
| Earnings (TTM) | -US$9.25m |
| Revenue (TTM) | US$5.64m |
0.0x
P/S Ratio0.0x
P/E RatioIs BLPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLPH income statement (TTM) | |
|---|---|
| Revenue | US$5.64m |
| Cost of Revenue | US$0 |
| Gross Profit | US$5.64m |
| Other Expenses | US$14.89m |
| Earnings | -US$9.25m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 100.00% |
| Net Profit Margin | -164.06% |
| Debt/Equity Ratio | 0% |
How did BLPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 10:59 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bellerophon Therapeutics, Inc. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sally Yanchus | Brookline Capital Markets |
| Christopher James | FBR Capital Markets & Co. |
| Andrew Fein | H.C. Wainwright & Co. |